Background:
Prostate cancer is the second most diagnosed malignancy in men and the sixth leading cause of cancer mortality among males worldwide. The incidence rate of prostate cancer varies across the regions and populations new cases of prostate cancer were registered worldwide, representing 7.1% of all cancers in men.
Aim of study:
To assess prostatic biopsies from patients with prostatic cancer in a sample of Iraqi patients according to 2014 modified Gleason Grading and Grade groups, and to study the relation of Gleason grading and grade group with clinical and laboratory data available in patients case sheets (age and PSA level).
Material and methods:
A cross sectional study conducted in Department of Pathology/College of Medicine /Al-Nahrain University for a period from January 2021 to march 2022. Cases and control were collected from Baghdad Medical City /Ghazi Al-Hariri Hospital for Surgical Specialties, cases included 94 patients had prostatic carcinoma and control group included 57 patients with benign prostatic hyperplasia.
Results:
This study revealed the age distribution of patients with Benign Prostatic Hyperplasia ranged from (50-88) years and prostatic adenocarcinoma ranged from (50-82) years. Regarding prostatic specific antigen levels in prostatic adenocarcinoma 75 (79.8%) of cases had high prostatic specific antigen levels (4ng/mL or Higher) while in benign prostatic hyperplasia 22(14.6%) of cases had high prostatic specific antigen levels. The frequency of perineural invasion in studied sample 39.4%, while vascular invasion only 5.3%.
Conclusion:
There was no statistically significant association was found between Gleason score and age, the same applies to the Gleason grade group. Also no statistically, significant association was found between the Gleason grade group and prostatic specific antigen level, in addition, no correlation was found between Gleason score and prostatic specific antigen level. There is no correlation was found between Gleason score, and perineural invasion.
(FULL ARTICLE LINK) Read more ...
2024
|
|
|
